Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Oramas, Juana
NCT05874401: Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan	Recruiting	4	302	Europe, RoW	Trilaciclib, G1T28, CDK 4/6 inhibitor, cyclin-dependent kinase 4/6 inhibitor, Placebo, Topotecan, Hycamtin	G1 Therapeutics, Inc.	Extensive-stage Small-cell Lung Cancer	07/27	07/27
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)	Recruiting	3	170	Europe, Canada, Japan, US, RoW	Selpercatinib, LY3527723, LOXO-292, Placebo	Loxo Oncology, Inc., Eli Lilly and Company	Carcinoma, Non-Small-Cell Lung	05/27	08/32
NCT02941458: Thoracic Tumours Register	Recruiting	N/A	10000	Europe		Spanish Lung Cancer Group	Thoracic Tumors	12/25	12/30
Mielgo, Xabier
NADIM-ADJUVANT, NCT04564157: New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy	Active, not recruiting	3	210	Europe	Carboplatin, Paraplatin, Paclitaxel, Taxol, Nivolumab, Opdivo	Fundación GECP	Non-Small Cell Lung Cancer, Adjuvant Chemotherapy	04/30	04/31
LORLAPULM, NCT05167500: Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment	Completed	N/A	118	Europe	Lorlatinib, Lorviqua	Fundación GECP	Metastatic Non Small Cell Lung Cancer	12/22	12/22
NCT02941458: Thoracic Tumours Register	Recruiting	N/A	10000	Europe		Spanish Lung Cancer Group	Thoracic Tumors	12/25	12/30